<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721886</url>
  </required_header>
  <id_info>
    <org_study_id>20G.605</org_study_id>
    <nct_id>NCT04721886</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer</brief_title>
  <official_title>Interstitial Fluid Pressure Estimation in Breast Cancer Using 3D Subharmonic Signals From Contrast-Enhanced Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies the use of contrast-enhanced ultrasound (CEUS) in estimating&#xD;
      tissue pressure in patients with breast cancer. Diagnostic procedures, such as CEUS, may help&#xD;
      estimate tissue pressure noninvasively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine if the 3-dimensional (3D) subharmonic aided pressure estimation (SHAPE)&#xD;
      results can be used to estimate interstitial fluid pressures (IFPs) in breast tumor and its&#xD;
      surrounding tissue.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To determine if the malignancy of breast tumor can be predicted by the 3D SHAPE results.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo ultrasound without contrast. Patients then receive perflutren lipid&#xD;
      microspheres (Definity) intravenously (IV) over 15 minutes and undergo CEUS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between subharmonic aided pressure estimation (SHAPE) results and direct measurements of interstitial fluid pressure (IFP)</measure>
    <time_frame>At baseline</time_frame>
    <description>Pearson's correlation coefficients will be computed between SHAPE results and direct IFP measurements by Stryker compartment pressure monitoring system. A Pearson's correlation coefficient above 0.5 will be considered a successful outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prediction of malignancy of breast tumor by the 3-dimensional subharmonic aided pressure estimation results</measure>
    <time_frame>At baseline</time_frame>
    <description>Generalized linear mixed logistic or generalized estimating equations logistic modeling of tumor versus non-tumor samples will be used to explore the potential for using SHAPE results as a novel functional predictor of breast tumor malignancy. Additionally, the subharmonic signal ratio from the tumor will be used to predict the malignancy of breast tumor using a biopsy result as a gold standard. The Mann-Whitney or Student's t-test will be performed depending on the distribution of the results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo ultrasound without contrast. Patients then receive Definity IV over 15 minutes and undergo CEUS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasonsgraphy</intervention_name>
    <description>Undergo ultrasonography</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>2-Dimensional Grayscale Ultrasound Imaging</other_name>
    <other_name>2-Dimensional Ultrasound Imaging</other_name>
    <other_name>2D-US</other_name>
    <other_name>Ultrasonography</other_name>
    <other_name>ultrasound</other_name>
    <other_name>Ultrasound Imaging</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflutren Lipid Microcpheres</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>Definity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast - Enhanced Ultrasound</intervention_name>
    <description>Undergo CEUS</description>
    <arm_group_label>Diagnostic (CEUS)</arm_group_label>
    <other_name>CEUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed and dated informed consent form&#xD;
&#xD;
          -  Be conscious, willing and able to comply with all study procedures and be available&#xD;
             for the duration of the study&#xD;
&#xD;
          -  At least 21 years old&#xD;
&#xD;
          -  Be scheduled for a breast biopsy (Breast Imaging Reporting and Data System [BIRAD] 4,&#xD;
             4A, 4B, 4C or 5)&#xD;
&#xD;
          -  Patient with an at least 1 cm mass located at &lt; 3 cm depth, approachable by 2.5 inch&#xD;
             needle&#xD;
&#xD;
          -  Be medically stable as determined by the investigator&#xD;
&#xD;
          -  If a female of child-bearing potential, must have a negative urine pregnancy test&#xD;
             within 24 hours prior to administration of Definity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
&#xD;
          -  Patients who are medically unstable, patients who are seriously or terminally ill, and&#xD;
             patients whose clinical course is unpredictable. For example:&#xD;
&#xD;
          -  Patients on life support or in a critical care unit&#xD;
&#xD;
          -  Patients with unstable occlusive disease (e.g., crescendo angina)&#xD;
&#xD;
          -  Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular&#xD;
             tachycardia&#xD;
&#xD;
          -  Patients with uncontrolled congestive heart failure (New York Heart Association [NYHA]&#xD;
             class IV)&#xD;
&#xD;
          -  Patients with recent cerebral hemorrhage&#xD;
&#xD;
          -  Patients who have undergone surgery within 24 hours prior to the study sonographic&#xD;
             examination&#xD;
&#xD;
          -  Patients with known hypersensitivity or allergy to any component of Definity&#xD;
&#xD;
          -  Patients with unstable cardiopulmonary conditions or respiratory distress syndrome&#xD;
&#xD;
          -  Patients with uncontrollable emphysema, pulmonary vasculitis, pulmonary hypertension&#xD;
             or a history of pulmonary emboli&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kiba Nam, MD</last_name>
    <phone>215-955-6261</phone>
    <email>Kibo.Nam@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kibo Nam, MD</last_name>
      <phone>215-955-6261</phone>
      <email>Kibo.Nam@jefferson.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

